Safety and Efficacy of a Circumferential Clip-Based Vascular Closure Device in Cirrhotic and Coagulopathic Patients with Hepatocellular Carcinoma After Doxorubicin Drug-eluting Beads Transarterial Chemoembolization

Prajapati, Hasmukh J.; Rafi, Shoaib; Edalat, Faramarz; Kooby, David A.

doi:10.1007/s00270-013-0709-9

Cited by 8 publications

(2 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Circumferential clip-based arterial closure device was used for hemostasis at the femoral artery access site. 26 Patients were observed for 3 hours in postprocedure area, underwent contrast-enhanced anatomic and DWI MR, and subsequently discharged home. Patients were followed up in interventional oncology clinics and by MRI at 4 weeks.…”

Section: Deb-tace Procedures and Clinical Follow-upmentioning

confidence: 99%

Immediate post‐doxorubicin drug‐eluting beads chemoembolization Mr Apparent diffusion coefficient quantification predicts response in unresectable hepatocellular carcinoma: A pilot study

Kokabi

Camacho

Xing

et al. 2015

Magnetic Resonance Imaging

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Deb-tace Procedures and Clinical Follow-upmentioning

confidence: 99%

Immediate post‐doxorubicin drug‐eluting beads chemoembolization Mr Apparent diffusion coefficient quantification predicts response in unresectable hepatocellular carcinoma: A pilot study

Kokabi

Camacho

Xing

et al. 2015

Magnetic Resonance Imaging

Self Cite

View full text Add to dashboard Cite

show abstract

“…The preplanned 90 Y dose was then administered at the recommended low pressure of 20 to 40 psi . To achieve hemostasis at the femoral arteriotomy site, a circumferential, clip‐based vascular closure device was used . 90 Y Bremsstrahlung SPECT/CT ascertained the delivery of radiopharmaceuticals to targeted lesions immediately after therapy in every patient .…”

Section: Methodsmentioning

confidence: 99%

Open‐label prospective study of the safety and efficacy of glass‐based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis

Kokabi

Camacho

Xing

et al. 2015

Cancer

Self Cite

View full text Add to dashboard Cite

BACKGROUND:The safety and efficacy of yttrium 90 ( 90 Y) therapy for unresectable infiltrative hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) requires further evaluation. METHODS: A prospective, single-center safety and feasibility study recruited patients with unresectable (Barcelona Clinic Liver Cancer stage C) infiltrative HCC with PVT. Safety was assessed according to Common Terminology Criteria for Adverse Events version 4.0. Overall survival (OS) and time to progression (TTP) were measured from the first 90 Y therapy. Survival analysis was performed with Kaplan-Meier estimation. Prognostic factors were tested with a log-rank test and Cox proportional regression analysis. RESULTS: Overall, 45 patients were recruited, and 30 patients who met the study's inclusion criteria underwent glass-based 90 Y therapy. Four patients (13%) had transient hepatobiliary toxicity (grade 2). Ten patients (33%) had related emergency department visits, with 5 patients (17%) requiring short-term hospitalization. No radiation pneumonitis, gastrointestinal ulceration, or procedure-related mortality occurred. The median OS was 13 months (95% confidence interval, 4.4-22 months) with a TTP of 9 months (95% confidence interval, 6.2-13.1 months). Absence of ascites, an international normalized ratio < 1.2, an Eastern Cooperative Oncology Group (ECOG) performance status of 0, Child-Pugh class A, a macroaggregated albumin lung shunt fraction (LSF) < 10%, and no hepatobiliary toxicity were significant predictors of prolonged OS according to a univariate analysis (P <.05). A multivariate analysis found an ECOG performance status of 0, Child-Pugh class A, an LSF < 10%, and lack of transient hepatobiliary toxicity (grade 2) to be independent predictors of prolonged OS (P <.05). An ECOG performance status of 0, ChildPugh class A, and an LSF < 10% were also predictors of prolonged TTP according to the multivariate analysis (P <.05). CONCLU-SIONS: In patients with unresectable infiltrative HCC and PVT, 90 Y therapy appears to be a safe and viable therapy. Cancer 2015;121:2164-74.

show abstract

Surgery in the Thrombocytopenic and Coagulopathic Patient

Holzen

Agarwal

Schwarz

2016

Surgical Emergencies in the Cancer Patient

View full text Add to dashboard Cite

Safety and Efficacy of a Circumferential Clip-Based Vascular Closure Device in Cirrhotic and Coagulopathic Patients with Hepatocellular Carcinoma After Doxorubicin Drug-eluting Beads Transarterial Chemoembolization

Cited by 8 publications

References 43 publications

Immediate post‐doxorubicin drug‐eluting beads chemoembolization Mr Apparent diffusion coefficient quantification predicts response in unresectable hepatocellular carcinoma: A pilot study

Immediate post‐doxorubicin drug‐eluting beads chemoembolization Mr Apparent diffusion coefficient quantification predicts response in unresectable hepatocellular carcinoma: A pilot study

Open‐label prospective study of the safety and efficacy of glass‐based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis

Surgery in the Thrombocytopenic and Coagulopathic Patient

Contact Info

Product

Resources

About